High-affinity binding of [3H]cimetidine to a heme-containing protein in rat brain

Drug Metabolism and Disposition

Volumn 36, Issue 3, 2008, Pages 614-621

  Stadel, Rebecca ^a   Yang, Jun ^a   Nalwalk, Julia W ^a   Phillips, James G ^b   Hough, Lindsay B ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b Curragh Chemistries   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4(5) (BENZYLTHIOMETHYL IH IMIDAZOLE; 4(5) [(4 IODOBENZYL) THIOMETHYL] 1H IMIDAZOLE; CIMETIDINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; KETOCONAZOLE; TRANYLCYPROMINE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; BRAIN; CIMETIDINE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HISTAMINE H2 ANTAGONISTS; ISOENZYMES; KINETICS; LIGANDS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TRITIUM;

RATTUS;

EID: 40849139362     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017889     Document Type: Article

References (48)

1. Back DJ and Tjia JF (1991) Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 32:624-626.
2. Baranová J, Anzenbacherova E, Anzenbacher P, and Soucek P (2005) Minipig cytochrome P450 2E1: comparison with human enzyme. Drug Metab Dispos 33:862-865.
3. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, and Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45:1211-1214.
4. 3H-cimetidine in brain. Eur J Pharmacol 50:449-450.
5. Cannon KE, Fleck MW, and Hough LB (2004) Effects of cimetidine-like drugs on recombinant GABAA receptors. Life Sci 75:2551-2558.
6. 2 receptors in rat renal glomeruli. Biochem Pharmacol 31:367-375.
7. Chauret N, Gauthier A, Martin J, and Nicoll-Griffith DA (1997) In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab Dispos 25:1130-1136.
8. Cohen LH, Remley MJ, Raunig D, and Vaz AD (2003) In vitro drug interactions of cytochrome P450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos 31:1005-1015.
9. Correia MA and Ortiz de Montellano PR (2005) Inhibition of cytochrome P450 enzymes, in Cytochrome P450 Structure, Mechanism, and Biochemistry (Ortiz de Montellano PR ed) pp 247-322, Kluwer Academic/Plenum Publishers, New York.
10. Devane WA, Dysarz FA III, Johnson MR, Melvin LS, and Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613.
11. 3H-cimetidine specific binding in rat anterior pituitary. Eur J Pharmacol 63:91-93.
12. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, and Ball SE (2001) A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29:23-29.
13. Dixon M and Webb EC (1964) Enzyme inhibitors, in Enzymes, pp 337-341, Academic Press Inc., New York.
14. Draper AJ, Madan A, and Parkinson A (1997) Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 341:47-61.
15. Erickson DA, Mather G, Trager WF, Levy RH, and Keirns JJ (1999) Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 27:1488-1495.
16. Foster AB, Jarman M, Leung CS, Rowlands MG, Taylor GN, Plevey RG, and Sampson P (1985) Analogues of aminoglutethimide: selective inhibition of aromatase. J Med Chem 28:200-204.
17. 3H-tiotidine to histamine H2 receptors in guinea pig cerebral cortex. Nature 304:65-67, 1983.
18. Goodman LS, Gilman AG, Hardman JG, and Limbird LE (2001) Agents used for control of gastric acidity and treatment of peptic ulcers, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Hardman JG, Limbird LE, and Gilman AG eds) pp 1005-1020, McGraw-Hill, New York.
19. Guengerich FP (1991) Reactions and significance of cytochrome P-450 enzymes. J Biol Chem 266:10019-10022.
20. Ha-Duong NT, Dijols S, Macherey A-C, Goldstein JA, Dansette PM, and Mansuy D (2001) Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 40:12112-12122.
21. 3H]cimetidine binding, is an improgan antagonist. Neuropharmacology 52:1244-1255.
22. Ignarro LJ, Harbison RG, Wood KS, Wolin MS, McNamara DB, Hyman AL, and Kadowitz PJ (1985) Differences in responsiveness of intrapulmonary artery and vein to arachidonic acid: mechanism of arterial relaxation involves cyclic guanosine 3′:5′-monophosphate and cyclic adenosine 3′:5′-monophosphate. J Pharmacol Exp Ther 233:560-569.
23. Inaba T, Jurima M, Mahon WA, and Kalow W (1985) In vitro inhibition studies of two isozymes of human liver cytochrome P-450: mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 13:443-448.
24. Jung F, Griffin KJ, Song W, Richardson TH, Yang M, and Johnson EF (1998) Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19. Biochemistry 37:16270-16279.
25. Kerlan V, Dreano Y, Bercovici JP, Beaune PH, Floch HH, and Berthou F (1992) Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. Biochem Pharmacol 44:1745-1756.
26. Kitada M, Chiba K, Kamataki T, and Kitagawa H (1977) Inhibition by cyanide of drug oxidations in rat liver microsomes. Jpn J Pharmacol 27:601-608.
27. Ko JW, Desta Z, Soukhova NV, Tracy T, and Flockhart DA (2000) In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol 40:343-351.
28. Levine M, Law EY, Bandiera SM, Chang TK, and Bellward GD (1998) In vivo cimetidine inhibits hepatic CYP2C6 and CYP2C11 but not CYP1A1 in adult male rats. J Pharmacol Exp Ther 284:493-499.
29. Madeira M, Levine M, Chang TK, Mirfazaelian A, and Bellward GD (2004) The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. Drug Metab Dispos 32:460-467.
30. Marini S, Grasso E, Longo V, Puccini P, Riccardi B, and Gervasi PG (2003) 4-Biphenylaldehyde and 9-anthraldehyde: two fluorescent substrates for determining P450 enzyme activities in rat and human. Xenobiotica 33:1-11.
31. Martínez C, Albet C, Agundez JA, Herrero E, Carrillo JA, Marquez M, Benitez J, and Ortiz JA (1999) Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther 65:369-376.
32. Masubuchi Y, Saito H, and Horie T (1998) Structural requirements for the hepatotoxicity of nonsteroidal anti-inflammatory drugs in isolated rat hepatocytes. J Pharmacol Exp Ther 287:208-213.
33. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, and Birkett DJ (1988) Tolbutamide hydroxylation by human liver microsomes: kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol 37:1137-1144.
34. Otyepka M, Skopalik J, Anzenbacherova E, and Anzenacher P (2007) What common structural features and variations of mammalian P450s are known to date? Biochim Biophys Acta 1770:376-389.
35. Park SS, Waxman DJ, Lapenson DP, Schenkman JB, and Gelboin HV (1989) Monoclonal antibodies to rat liver cytochrome P-450 2c/RLM5 that regiospecifically inhibit steroid metabolism. Biochem Pharmacol 38:3067-3074.
36. Reilly PE, Carrington LE, and Winzor DJ (1983) The interaction of cimetidine with rat liver microsomes. Biochem Pharmacol 32:831-835.
37. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448.
38. 3H-cimetidine binding in guinea-pig tissues. Life Sci 27:199-206.
39. 3H]cimetidine to rat brain tissue. Agents Actions 10:422-426.
40. Sorkin EM and Darvey DL (1983) Review of cimetidine drug interactions. Drug Intell Clin Pharm 17:110-120.
41. Spatzenegger M, Wang Q, He YQ, Wester MR, Johnson EF, and Halpert JR (2001) Amino acid residues critical for differential inhibition of CYP2B4, CYP2B5, and CYP2B1 by phenylimidazoles. Mol Pharmacol 59:475-484.
42. Stresser DM (2004) High-throughput screening of human cytochrome P450 inhibitors using fluorometric substrates, in Optimization in Drug Discovery (Yan Z and Caldwell G eds) pp 215-229, Humana Press Inc., Totowa, NJ.
43. Stresser DM, Turner SD, McNamara J, Stocker P, Miller VP, Crespi CL, and Patten CJ (2000) A high-throughput screen to identify inhibitors of aromatase (CYP19). Anal Biochem 284:427-430.
44. Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, and Pelkonen O (2004) Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos 32:626-631.
45. 2-receptor. Life Sci 33:1119-1126.
46. Waxman DJ, Lapenson DP, Park SS, Attisano C, and Gelboin HV (1987) Monoclonal antibodies inhibitory to rat hepatic cytochromes P-450: P-450 form specificities and use as probes for cytochrome P-450-dependent steroid hydroxylations. Mol Pharmacol 32:615-624.
47. Wilkinson CF, Hetnarski K, and Yellin TO (1972) Imidazole derivatives - a new class of microsomal enzyme inhibitors. Biochem Pharmacol 21:3187-3192.
48. Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, and Sellers EM (2002) Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos 30:314-318.